2022
April 11, 2022 – NEUVOGEN Appoints Vaccine Manufacturing expert, Peter Watler, PhD as Head of Manufacturing Operations
March 28, 2022 – NEUVOGEN Appoints Biotechnology Veteran, Mark Backer, PhD as Head of Technical Operations
2021
December 21, 2021 – NEUVOGEN Announces Appointment of Chief Financial Officer
August 30, 2021 – NEUVOGEN Appoints Cellular Immune Therapy Expert, Dr. Jack Bui to its Scientific Advisory Board
August 23, 2021 – NEUVOGEN Appoints Dr. Mark W. Frohlich, a World-Renowned Immunotherapy Expert to its Board of Directors and Scientific Advisory Board
February 25, 2021 – NEUVOGEN Appoints Life Sciences Legal Advisor, Alan C. Mendelson to Board of Directors
March 28, 2022 – ImaginAb and NEUVOGEN Announce Licensing Agreement for CD8 ImmunoPET Technology
January 25, 2021 – NEUVOGEN Appoints Dr. Christian Ottensmeier Head of Scientific Advisory Board
January 20, 2021 – NEUVOGEN Announces Participation at B.Riley Virtual Oncology Investor Conference
January 20, 2021 – NEUVOGEN Announces Next Generation Cancer Vaccine Strategy to Transform how Solid Tumors are Treated